Our optimized pri-amiRNAs targeting HTT mRNA are undergoing an extensive evaluation of efficacy in the YAC128 mouse model of HD to demonstrate the therapeutic potential of an AAV gene therapy that exhibits efficient and precise pri-amiRNA processing along with potent pharmacological activity for HTT mRNA lowering. Here, HTT is linked to Huntington disease.